Provided by Janssen
Novenber 22, 2013
OLYSIO™(simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
OLYSIO™ is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease.
See Press Release here
No comments:
Post a Comment